The first domestic recombinant human papillomavirus vaccine was approved for marketing!

Recently, the State Food and Drug Administration approved the listing and registration application of the bivalent human papillomavirus vaccine (E.coli) (trade name: cecolin) of Xiamen Wantai Canghai Biotechnology Co., Ltd., which is the first approved domestic human papillomavirus vaccine for women aged 9-45 years Human papillomavirus (HPV) vaccine, commonly known as cervical cancer vaccine, can be used to prevent cervical cancer in women and genital cancer and genital warts in men and women At present, there are three kinds of HPV vaccines on the market in the world, namely, the bivalent vaccine for HPV16 and 18 produced by GlaxoSmithKline, the bivalent vaccine for HPV6, 11, 16 and 18 produced by MSD, and the bivalent vaccine for HPV6, 11, 16, 18, 31, 33, 45, 52 and 58 produced by MSD The approved bivalent human papillomavirus vaccine (e The State Food and drug administration shall, in accordance with the relevant provisions of the announcement on the optimization of matters related to the review and approval of drug registration, include it in the priority review varieties and accelerate the approval of its application for listing registration The approval of this product will further meet the public demand and improve the accessibility of the product Adorable adorable